Logo

Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

Share this

Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

Shots:

  • The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib)- Mektovi (binimetinib) & Erbitux (cetuximab) in patients with BRAF mutant mCRC
  • P-III BEACON CRC trial results: mOS 15.3 mos.; mPFS 8 mos.; ORR 48%; well-tolerated with no toxicities- will be presented at ASCO 2019
  • Braftovi (encorafenib)- Mektovi (binimetinib)- Erbitux (cetuximab) is a BRAF inhibitor- a MEK inhibitor and an anti-EGFR Ab respectively. On 7 Aug- 2018 Braftovi received FDA’s BT designation in combination with Mektovi & Erbitux for patients with 2L BRAF mutant mCR

Ref:  Array Biopharma Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions